ArticleWorld journal of urology2026
The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe C-reactive protein-albumin-lymphocyte index (CALLY), a composite inflammatory and nutritional biomarker, has shown prognostic utility in various cancers, but its role in metastatic hormone-sensitive prostate cancer (mHSPC) remains underexplored.
objectiveTo evaluate the association between baseline CALLY index and overall survival (OS) and time to castration-resistant prostate cancer (CRPC) in mHSPC patients.
methodsIn this retrospective cohort study, 192 mHSPC patients receiving first-line endocrine therapy (2017-2024) were stratified by median CALLY (30) into low-CALLY (30) and high-CALLY (≥ 30) groups. Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates. Weighted Cox models assessed associations with OS and CRPC-free survival. Subgroup analyses were conducted by age group, metastatic volume and first-line mHSPC therapy.
resultsAfter IPTW adjustment, a high baseline CALLY index was identified as an independent protective factor for both clinical endpoints. Specifically, patients in the high-CALLY group had a 71% reduced risk of all-cause mortality (adjusted hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.18-0.46, p < 0.001) and a 49% reduced risk of CRPC progression (adjusted HR 0.51, 95% CI 0.34-0.77, p = 0.001), compared with the low-CALLY group. The prognostic association remained consistent across all prespecified subgroups, with pronounced benefits observed in patients with high-volume metastatic disease and those receiving first-line bicalutamide. Sensitivity analyses (treating CALLY as a continuous variable, conventional multivariable Cox regression) and E-value assessment further confirmed the robustness and independence of the findings.
conclusionThe CALLY index is an accessible and independent prognostic biomarker for OS and CRPC progression in mHSPC. Its integration into clinical assessment could enhance risk stratification and support personalized treatment planning, potentially improving long-term patient outcomes.
Indexed as
Identifiers
41964875What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.